-+ 0.00%
-+ 0.00%
-+ 0.00%

Tentarix targets completion of AbbVie, Gilead partnered programs within 12 months

PUBT·11/19/2026 15:21:07
Tentarix targets completion of AbbVie, Gilead partnered programs within 12 months
  • Amplitude Ventures portfolio company Tentarix targets completion of partnered programs with AbbVie and Gilead within roughly 12 months.
  • Its internal pipeline is advancing toward the clinic, with several discovery-stage programs progressing toward IND-enabling studies.
  • Tentarix develops cell-targeted multispecific antibodies designed to reduce systemic toxicity, initially focusing on autoimmune diseases and solid tumors resistant to checkpoint inhibitors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplitude Ventures Inc published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.